NPC

New research examines whether state copay accumulator bans had an effect on premiums in commercial health insurance markets. See what the evidence says: 🧵

In a new commentary, NPC Chief Science Officer Jon Campbell & Melanie Whittington make the case for flexible, context-dependent cost-effectiveness thresholds as one contributor toward facilitating a competitive and successful marketplace.

Learn More: becarispublishing.com/digital-conten…

NPC is looking forward to sharing new research at the @RareDiseases #NORDSummit, which provides an opportunity to examine the research and policy considerations shaping rare disease care.

We’re proud to be @GPTW_US Certified once again. Our team makes NPC what it is: bringing curiosity and rigor to our research, communicating it with impact to inform policy conversations, and working together to build a culture people want to be part of. #GreatPlaceToWorkCertified

A new commentary on meaningful patient P&T representation in @Health_Affairs Forefront offers a practical framework for health plans to move beyond compliance toward meaningful change.

Read more: healthaffairs.org/content/forefr…